Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00293891 · ClinicalTrials.gov registry record · Phase 3
A Study to Assess the Safety and Effectiveness of Tacrolimus Cream in the Treatment of Psoriasis
A Phase 3 study of Psoriasis, sponsored by Astellas Pharma.
- Completed
- Registry status
- Phase 3
- Development phase
- 658
- Enrollment target
- 20
- Study locations
NCT00293891: Completed Phase 3 study of Psoriasis, sponsored by Astellas Pharma.
NCT00293891 is a Phase 3 study of Psoriasis that has completed, run by Astellas Pharma. The registered enrollment target is 658 participants, above the 483-participant average among 125 other Psoriasis trials with a reported enrollment target (36% higher). The trial reports 20 study locations across 17 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00293891, a Phase 3 study of Psoriasis, has completed, sponsored by Astellas Pharma.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 658 participants
- Enrollment target
- 20
- Study locations
Study Summary
A study to assess the safety and effectiveness of tacrolimus cream in the treatment of psoriasis.
Conditions Studied
Interventions
- DRUG Tacrolimus Cream
Study Locations (20)
Florida
- - Miami
- - West Palm Beach
Michigan
- - Ann Arbor
- - Port Huron
Ohio
- - Columbus
- - Dayton
Alabama
- - Birmingham
Arkansas
- - Little Rock
California
- - San Diego
Colorado
- - Denver
Georgia
- - Newnan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 658 participants |
| Est. Completion | 2007-01 |
| Phase | Phase 3 |
What the finished NCT00293891 record still lists
NCT00293891 is an interventional study that assigns participants to a tested intervention. The registered 658 participants enrollment target is mid-sized for trials with a published cap, above the 483-participant average among 125 other Psoriasis trials with a reported enrollment target (36% higher).
The record links to 1 condition, with Psoriasis appearing as the primary indexed condition, and to 1 intervention - of which Tacrolimus Cream is the first listed.
NCT00293891 names 20 study sites across 17 states, led by Florida, Michigan, Ohio.
Frequently Asked Questions
What is clinical trial NCT00293891 about?
NCT00293891 is a clinical study titled "A Study to Assess the Safety and Effectiveness of Tacrolimus Cream in the Treatment of Psoriasis". A study to assess the safety and effectiveness of tacrolimus cream in the treatment of psoriasis.
What is the current status of trial NCT00293891?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 658 participants. Estimated completion is 2007-01.
What conditions does trial NCT00293891 study?
This clinical trial studies the following conditions: Psoriasis.
What interventions are being tested in trial NCT00293891?
The interventions under investigation include: Tacrolimus Cream (DRUG).
Who is sponsoring clinical trial NCT00293891?
This trial is sponsored by Astellas Pharma, which has 165 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00293891 being conducted?
This trial has 20 study locations across Alabama, Arkansas, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Psoriasis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00293891's enrollment target sits among peer trials
658 15th of 125 higher than 111 of 125 other Psoriasis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Psoriasis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977
ACTIVE NOT RECRUITING · Phase 3
-
Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis
ACTIVE NOT RECRUITING · Phase 3
-
Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis
ACTIVE NOT RECRUITING · Phase 3
-
Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneously Administered Guselkumab for the Treatment of Chronic Plaque Psoriasis in Pediatric Participants
ACTIVE NOT RECRUITING · Phase 3
-
A Study of Subcutaneous Risankizumab Injection for Pediatric Participants With Moderate to Severe Plaque Psoriasis to Assess Change in Disease Symptoms
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07216742 · 659 participants · Phase 3
Human Menopausal Gonadotropin Research in Infertility Assessing Cumulative Live Birth With Frozen Embryo Transfer.
- NCT03671044 · 657 participants · Phase 3
A Study to Evaluate the Efficacy and Safety of Nanosomal Docetaxel Lipid Suspension in Triple Negative Breast Cancer Patients
- NCT05338697 · 657 participants
Validation of Early Prognostic Data for Recovery Outcome After Stroke for Future, Higher Yield Trials
- NCT01185132 · 660 participants · Phase 3
Intensity Modulated Radiotherapy (IMRT) vs. 3D-conformal Accelerated Partial Breast Irradiation (APBI) for Early Stage Breast Cancer After Lumpectomy